
Ask a doctor about a prescription for Bilagra
Bilastine
Bilagra contains the active substance bilastine, which has antihistamine properties.
Bilagra is used to relieve the symptoms of hay fever (sneezing, itching, runny nose, blocked nose, and red and itchy eyes) and other forms of allergic rhinitis. The medicine may also be used to treat itchy skin rashes (hives or urticaria).
Before taking Bilagra, discuss with your doctor or pharmacist if you have moderate or severe kidney problems, low potassium, magnesium, or calcium levels in your blood, if you have or have had heart rhythm problems or very slow heart rate, if you are taking medicines that may affect your heart rhythm, or if you have or have had an abnormal heart rhythm (known as QTc interval prolongation on an electrocardiogram), which may occur in certain types of heart disease, and you are taking other medicines (see "Bilagra and other medicines").
Do notexceed the recommended dose. If symptoms persist, consult your doctor.
Tell your doctor or pharmacist about all medicines you are taking, or have recently taken, and any you plan to take, including those obtained without a prescription.
In particular, inform your doctor about taking any of the following medicines:
asthis reduces the effect of bilastine. To avoid reducing the effect of the medicine, you should:
Bilastine at the recommended dose (20 mg) does not increase drowsiness caused by alcohol consumption.
There are no or limited data on the use of bilastine in pregnant or breastfeeding women, or on its effects on fertility.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. Before taking any medicine, consult your doctor or pharmacist.
It has been shown that taking bilastine at a dose of 20 mg does not affect the ability to drive in adults. However, the response to treatment may vary from person to person.
Therefore, before driving or operating machinery, check how the medicine affects you.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is essentially "sodium-free".
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose for adults, including the elderly, and adolescents 12 years and older is 1 tablet (20 mg) once daily.
Other forms of this medicine - bilastine 10 mg orodispersible tablet or bilastine 2.5 mg/mL oral solution - are intended for children from 6 to 11 years of age with a body weight of at least 20 kg - ask your doctor or pharmacist.
If you take more Bilagra than you should, immediatelycontact your doctor or pharmacist or go to the emergency department of your nearest hospital. Bring the medicine package or leaflet with you.
Do nottake a double dose to make up for a forgotten dose.
If you forget to take a dose, take the missed dose as soon as possible, and then continue with your regular dose at the usual time.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Bilagra can cause side effects, although not everybody gets them.
If you experience an allergic reaction, including: difficulty breathing, dizziness, fainting, or loss of consciousness, swelling of the face, lips, tongue, or throat, and (or) swelling and redness of the skin, stop taking the medicine and consult your doctor immediately.
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Frequency not known: cannot be estimated from the available data
Common: may affect up to 1 in 10 people
If you experience any side effects, including any not listed in this leaflet, tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Post-Marketing Surveillance of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, Website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after "EXP". The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Bilagra tablets are round, white or almost white, biconvex tablets with a diameter of about 7 mm.
The tablets are packaged in blisters of 10, 20, 30, 50, or 100 tablets, and in single-dose blisters of 10x1, 20x1, 30x1 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder
Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands
Manufacturer/Importer
Saneca Pharmaceuticals a.s.
Nitrianska 100
920 27 Hlohovec
Slovakia
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Bilagra – subject to medical assessment and local rules.